New drugs and dosage forms

January 2011
American Journal of Health-System Pharmacy;1/1/2011, Vol. 68 Issue 1, p6
Academic Journal
The article presents information on several new drugs along with their dosage forms, including the Baclofen injection for intrathecal use, Denosumab injection for subcutaneous use, and Testosterone topical solution for replacement therapy in men with hypogonadism.


Related Articles

  • research update. MS Spasticity: Take Control! Hugos, Cinda // PN;Dec2010, Vol. 64 Issue 12, p40 

    The article offers the author's insights on multiple sclerosis (MS) spasticity management. It states that the author, along with Lois Copperman and the National MS Society, has developed a DVD program on spasticity guideline titled "MS Spasticity: Take Control." It mentions that the DVD program...

  • Ustekinumab: a guide to its use in plaque psoriasis. Keating, Gillian M.; Croxtall, Jamie D. // Drugs & Therapy Perspectives;Aug2012, Vol. 28 Issue 8, p6 

    Subcutaneous ustekinumab (Stelara®) improves symptoms in patients with moderate to severe plaque psoriasis and is more effective than etanercept. Subcutaneous ustekinumab is generally well tolerated, with infections being the most commonly reported adverse event.

  • Estradiol and testosterone modulate the anesthetic action of the GABA-A agonist THIP, but not of the neurosteroid 3α,5β-pregnanolone in the rat. González-Flores, Oscar; Sánchez, Norma; García-Juárez, Marcos; Lima-Hernández, Francisco Javier; González-Mariscal, Gabriella; Beyer, Carlos // Psychopharmacology;2004, Vol. 172 Issue 3, p283 

    Rationale. As sex steroids modify the number and distribution of brain γ-aminobutyric acid (GABA)[sub A] receptor subunits, we investigated the potential modulation of anesthesia, induced by agents acting on the GABA[sub A] receptor, by estrogen and androgen. Objectives. To assess possible...

  • Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi. Kennel, S J; Boll, R; Stabin, M; Schuller, H M; Mirzadeh, S // British Journal of Cancer;4/15/99, Vol. 80 Issue 1/2, p175 

    A model system has been used to test the efficacy of vascular targeting of α-particle emitter [SUP213]Bi for therapy of small, 'artificial' metastases in mouse lung. Specific monoclonal antibody (mAb) 201B was used to deliver greater than 30% of the injected dose to lung where tumours had...

  • Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. Di Bartolomeo, Maria; Pietrantonio, Filippo; Martinetti, Antonia; Buzzoni, Roberto; Gevorgyan, Arpine; Bajetta, Emilio // Drugs & Aging;2011, Vol. 28 Issue 2, p83 

    Although major progress has been achieved in the treatment of metastatic colorectal cancer with the employment of biological antiangiogenic agents, several questions remain open for discussion regarding the use of this therapy in elderly patients with metastatic colorectal cancer. In Western...

  • The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity. Tastekin, Didem; Tambas, Makbule; Kilic, Kemal; Erturk, Kayhan; Arslan, Deniz // Investigational New Drugs;Dec2014, Vol. 32 Issue 6, p1295 

    This open-labeled phase II, efficacy-finding study evaluated the efficiency and safety of Pistacia terebinthus soap in metastatic colorectal cancer patients who developed cetuximab induced skin toxicity. Patients who received cetuximab plus chemotherapy and developed Grade 2 or 3 skin toxicity...

  • Response to Ameisen. Addolorato, Giovanni; Leggio, Lorenzo // Alcohol & Alcoholism;Jul/Aug2011, Vol. 46 Issue 4, p504 

    A response by Giovanni Addolorato and colleagues to a letter to the editor on their article "Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial" in the 2011 issue is presented.

  • Baclofen: What's in a Word? A World of Difference. Ameisen, Olivier // Alcohol & Alcoholism;Jul/Aug2011, Vol. 46 Issue 4, p503 

    A letter to the editor is presented in response to the article "Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial," by Giovanni Addolorato and colleagues in the 2011 is presented.

  • Clinical Experience with Baclofen in the Management of Alcohol-Dependent Patients with Psychiatric Comorbidity: A Selected Case Series. Dore, G.M.; Lo, K.; Juckes, L.; Bezyan, S.; Latt, N. // Alcohol & Alcoholism;Nov/Dec2011, Vol. 46 Issue 6, p714 

    Aims: To illustrate the potential indications for, and adverse effects of, baclofen pharmacotherapy for alcohol dependence in patients with co-existing psychiatric illness. Methods: Audit of the files of alcohol-dependent patients treated for comorbid non-psychotic psychiatric illness in a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics